DGAP-News: curasan AG

- Subscription rights for 2,275,786 new shares exercised

- 1,876,070 new shares to be acquired by strategic investor as agreed

Kleinostheim, 4 October 2017 - The Management Board of curasan AG (ISIN DE0005494538) today, with the consent of the Supervisory Board, decided to increase the volume of the capital increase agreed on 4 September 2017 to EUR 4,151,856.00.

The shares were offered to the existing shareholders from 11 September to 25 September 2017 by way of indirect subscription right in a 22:8 ratio. During the subscription period subscription rights were exercised for 2,275,786 new shares. The remaining 1,876,070 new shares from the capital increase are to be acquired by a strategic investor from China on the basis of an investment agreement signed on 4 September 2017 at a price of EUR 1.20.

At present, a necessary authorization for the capital transfer from the investor to the company is still pending. The Management Board of curasan AG has therefore decided today, with the consent of the Supervisory Board, to implement the capital increase in two parts in order to be able to provide the remaining shareholders with the shares related to the subscription offer in advance.

In the course of the first partial implementation of the capital increase, the company's capital will in a first step be increased from EUR 11,417,610.00 by a nominal EUR 2,275,786.00 to EUR 13,693,397.00 by the issuance of 2,275,786 new bearer shares (with a calculated share of the share capital of EUR 1.00 per share) against cash contributions. The new shares will carry dividend rights from 1 January 2017.

The first part of the capital increase is expected to be entered into the commercial register on or around 10 October 2017. The new shares are expected to be included in the existing listing of the company's shares in the regulated market of the Frankfurt Stock Exchange by mid-October 2017.

Through the first tranche of the capital increase, curasan AG generates gross proceeds of around EUR 2.7 million. This is primarily to be used for further

market development in Asia and North America. All the prerequisites for the further partial implementation of the capital increase are currently expected to be in place by the end of October 2017

curasan develops, manufactures and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. As a pioneer and global technology leader in the growing field of regenerative medicine, curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications, i.e. materials mimicking biological structures. Numerous patents and a broad record of scientific publications demonstrate the clinical success of the products and the highly innovative strength of curasan. Dental and orthopaedic clinicians worldwide benefit from the broad range of the premium quality and easy to use portfolio offered by the technology leader curasan. curasan maintains its own high-tech facilities for research, development and manufacturing of biomaterials in Frankfurt/Main, Germany. In addition to its headquarters, the company has a subsidiary, curasan, Inc., in the Research Triangle Park area, near Raleigh, N.C., USA. curasan's innovative products are cleared by the US Food and Drug Administration (FDA) and many other international authorities and available in almost 50 countries worldwide. curasan AG is a public company listed in the General Standard at the Frankfurt Stock Exchange.